Secondary Logo

Institutional members access full text with Ovid®

Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia

Desai, Ankita P. MD*†; Sharma, Dolly MD; Crispell, Emily K. BS*§¶; Baughman, Wendy MSPH§¶; Thomas, Stepy MSPH§¶; Tunali, Amy MPH§¶; Sherwood, Logan BS; Zmitrovich, April MSW, MPH; Jerris, Robert PhD*†; Satola, Sarah W. PhD*§¶; Beall, Bernard PhD; Moore, Matthew R. MD; Jain, Shabnam MD, MPH*†; Farley, Monica M. MD*§¶

The Pediatric Infectious Disease Journal: November 2015 - Volume 34 - Issue 11 - p 1168–1174
doi: 10.1097/INF.0000000000000849
Original Studies
Buy
SDC

Background: Streptococcus pneumoniae (SP) serotype distribution among nasopharyngeal (NP) carriage isolates changed significantly after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). We evaluated the impact on NP carriage and invasive disease of SP after the introduction of the 13-valent PCV (PCV13) in March 2010.

Methods: NP swabs were collected from children 6–59 months of age in an emergency department from July 2010 to June 2013. After broth enrichment, samples were cultured for SP and isolates were serotyped. Clinical and immunization records were reviewed. Findings during 6 sequential 6-month study periods were compared. Surveillance isolates of invasive disease isolates were reviewed.

Results: A total of 2048 children were enrolled, and 656 (32%) were SP carriers. Mean age of carriers was 27 months, 54% were males. Carriage was higher among day-care attendees (P < 0.01) and children with respiratory tract illnesses (P < 0.5) and otitis media (P < 0.01). Commonly carried serotypes included 35B (15.2%), 15B/C (14.2%), 19A (9.6%), 11A (8%), 23B (5.6%), 6C (5.3%), 21 (5%), and 15A (5%); 13.9% were PCV13 serotypes. The proportion of children with SP carriage remained stable but the serotype distribution changed during the study period. Among carriers, PCV13 serotypes declined from 29% (36/124) to 3% (3/99; P < 0.0001), predominantly because of decline of serotype 19A from 25.8% (32/124) to 3% (3/99; P < 0.0001); non-PCV13 serotypes (excluding 6C) increased from 68.4% (78/114) to 97% (95/98; P < 0.0001); serotype 35B significantly increased from 8.9% (11/124) to 25.3% (25/99; P < 0.05). Nonsusceptibility to ceftriaxone declined from 22.6% (28/124) to 0% (0/99; P < 0.0001), with a similar decline in penicillin nonsusceptibility.

Conclusions: Introduction of PCV13 for universal infant use was associated with significant reductions in nasopharyngeal carriage of PCV13 serotypes and resistant strains. Carriage of non-PCV13 serotypes increased modestly, particularly serotype 35B. Further investigation is warranted to determine whether nonvaccine pneumococcal serotypes carried in the nasopharynx are associated with significant replacement disease.

Supplemental Digital Content is available in the text.

From the *Emory University School of Medicine, Atlanta, Georgia; Children’s Healthcare of Atlanta, Atlanta, Georgia; Women and Children’s Hospital of Buffalo, University at Buffalo, The State University of New York, Buffalo, New York; §Georgia Emerging Infections Program, Atlanta, Georgia; Veterans Affairs Medical Center, Atlanta, Georgia; and Division of Bacterial Diseases, Respiratory Diseases Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.

Ankita P. Desai, MD is currently at the Rainbow Babies and Children’s Hospital, Case Western Reserve University, Cleveland, Ohio.

Accepted for publication May 21, 2015.

Part of this work was presented at the 8th International Symposium on Pneumococci and Pneumococcal Disease in Iguassu Falls, Brazil in March 2012 (Abstract no. 665), the Pediatric Academic Society Annual Meeting in Boston, USA in April 2012 (Publication no. 2915.202) and at the Inaugural ID Week in San Diego, California, USA in October 2012 (Abstract no. 36589).

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Address for correspondence: Ankita Desai, MD, 11100 Euclid Avenue, Cleveland, Ohio 44106. E-mail: kita.desai@gmail.com.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.